Erin Bastick
Erin Bastick is a PharmD Candidate 2016, Ohio Northern University, Ada, Ohio, and an inpatient intern at University Hospitals, Cleveland.
FDA approves Veltassa to treat hyperkalemia
FDA approved patiromer (Veltassa, Relypsa) oral suspension for the treatment of hyperkalemia. Hyperkalemia is the condition when blood potassium levels are higher than normal in the kidneys, which can lead to abnormal heart rhythms or sometimes death.
Injectable schizophrenia drug gets FDA green light
FDA has approved aripiprazole lauroxil (Aristada, Alkermes) extended-release injectable suspension for the treatment of adults with schizophrenia.
FDA approves cariprazine for treatment of schizophrenia
FDA has approved cariprazine (Vraylar, Allergan and Gedeon Richter Plc.) for the treatment of schizophrenia and bipolar I disorder in adults.
FDA approves long-acting insulin drugs
FDA approved Tresiba (insulin degludec injection, Novo Nordisk) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection, Novo Nordisk) for the treatment of diabetes mellitus.
FDA accepts NDA for first 'digipill'
Proteus Digital Health along with the pharmaceutical company, Otsuka, has submitted the first Digital Medicine New Drug Application (NDA) for the combination tablet of Abilify (aripiprazole) embedded with a Proteus ingestible sensor.
FDA expands Brilinta approval for long-term use in patients with heart attack history
FDA has expanded approval for ticagrelor (Brilinta, AstraZeneca) to include long-term use in patients with a history of heart attack.
New aspirin formulation approved for secondary prevention of stroke, cardiac events
FDA approved aspirin extended release capsules (Durlaza, New Haven Pharmaceuticals, Inc.) for the prevention of stroke and acute cardiac events.
FDA approves Varubi for chemotherapy-induced nausea
FDA has approved rolapitant (Varubi, Tesaro) for the prevention of chemotherapy-induced nausea and vomiting.
FDA approves Synjardy for type 2 diabetes
FDA has approved empagliflozin and metformin hydrochloride (Synjardy, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company) tablets for the treatment of adults with type 2 diabetes.
FDA expands pediatric age indication for Promacta
FDA has expanded approval of eltrombopag (Promacta, Novartis) to treat low blood platelet count in pediatric patients with chronic immune thrombocytopenic purpura.